Treatment of platelet derived growth factor related disorders such as cancers

A method of treating a patient suffering from a fibrotic disorder characterized by inappropriate PDGF-R activity, comprising the step of administering to said patient a therapeutically effective amount of a composition comprising a compound selected from the group consisting of:

• a) a Group 1 compound having the chemical structure:
• ##STR11## wherein R.sub.1, R.sub.2, R'.sub.2, R".sub.2, and R'".sub.2 are independently selected from the group consisting of hydrogen, halogen, trihalomethyl, and NO.sub.2 ;
• and R.sub.3 is selected from the group consisting of hydrogen, carboxy, and carbalkoxy,
• b) a Group 2 compound having the chemical structure:
• ##STR12## wherein R.sub.4 and R.sub.5 are independently halogen, hydrogen, trihalomethyl, or NO.sub.2 ;
• and R.sub.6 is either aryl, alkyl, alkenyl, and alkynyl, and
• c) the active drug of said compound, or a pharmaceutically acceptable salt of said compound,
• wherein said compound significantly inhibits one or more PDGF-R activities in vivo or in vitro.